Rassuli M, Sajjadi M. The Islamic Republic of Iran. In “Cancer care in countries and societies in transition” M. Silbermann. Springer International Publishing Switzerland. 2016: 317-326.
Mousavi S. Executive guideline for registering and reporting cancer cases. In “Cancer Office and the Research fellowship of Cancer Research Center of Cancer Institute: Tehran”.2007: 122.
Bazyar M, Pourreza A, Harirchi I, Akbar FE, Mahmoudi M. Medical and non-medical direct costs of cancers in patients hospitalized in Imam Khomeini cancer institution-2010. J Hospital 2012; 11: 39–50.
Ya-chen TS, Michael TH. Economic evaluation of medical care intervention for cancer patients: How, Why and what does it mean? CA Cancer J Clin 2008; 58: 231-244.
Daroudi R, Mirzania M, Zendehdel K. Attitude of Iranian medical oncologists toward economic aspects and policy-making in relation to new cancer drugs. Int J Health Policy Manag 2016; 5: 99-105.
Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Affairs 2010; 29: 196-202.
Shahabi S, Fazlalizadeh H, Stedman J, Chuang L, Shariftabrizi A, Ram R. The impact of international economic sanctions on Iranian cancer health care. Health Policy 2015; 119: 1309-1318.
Sarkhanlou F, Saeedi M, Janbabai G, Nikfar S, Morteza-semnani K, Zaboli P. Comparative study of direct patient and drug costs before and after the implication of healthcare reform program in Sari, Iran. J Mazandaran Univ Med Sci 2016; 26: 228-232.
Ansaripour A, Zendehdel K, Tadayon N, Sadeghi F, Uyl-de GC, Redekop WK. Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran. Value Health 2016;19: A355.
Foroughi moghadam MJ, Rangchian M, Ayati M, Pourmand G, Zeinali L, Rasekh HR. Economic burden of prostate cancer in Iran. Value Health 2016;19: A147.
Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic burden of hepatitis C virus infection in different stages of disease: A report from southern Iran. Hepat Mon 2016; 16: e32654.
Rezaei S, Sari AA. Estimating economic burden of cancer deaths attributable to smoking in Iran in 2012. J Res Health Sci 2016; 16:97.
Izadi A, Sirizi MJ, Esmaeelpour S, Barouni M. Evaluating Direct Costs of Gastric Cancer Treatment in Iran - Case Study in Kerman City in 2015. Asian Pac J Cancer Prev 2016; 17:3007-3013.
Karami-matin B, Najafi F, Rezaei S, Khosravi A, Soofi M. Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010. Asian Pac J Cancer Prev 2016; 17:2131-2136.
Sari AA, Rezaei S, Arab M, Majdzadeh R, Matin BK, Zandian H. Effects of Smoking on Cost of Hospitalization and Length of Stay among Patients with Lung Cancer in Iran: A Hospital-Based Study. Asian Pac J Cancer Prev 2016; 17:4421-4426.
Ansaripour A, Zendehdel K, Uyl-de groot CA, Naemisanatdost A, Redekop WK. Direct medical costs of HER2 positive breast cancer management in Iran: A claims database and data mining analysis. Value Health 2015;18: A199-A200.
Khorasani S, Rezaei S, Rashidian H, Daroudi R. Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran. Asian Pac J Cancer Prev 2015; 16:1845-1850.
Davari M, Yazdanpanah F, Aslani A, Hosseini M, Nazeri AR, Mokarian F. The direct medical costs of breast cancer in Iran: Analyzing the patient's level data from a cancer specific hospital in Isfahan. Int J Prev Med 2013; 4:748-754.
Bazyar M, Barfar E. Cost analysis for cancer subgroups in Kerman. Iran J Epidemiol 2013; 9:69-72.
Rezapour A, Ghaderi H, Ebadifardazar F, Sofla AS. Microeconomic analysis of health care services delivered to patients under urologic tumor surgeries. HealthMED 2012; 6:4141-4151.
Farokhi noori MR, Holakouie NK, Haghdoost AA, Emami A. Cost analysis for cancer subgroups in Kerman, IRAN. Iran J Epidemiol 2012; 8:62-70.
Mohagheghi MA, Mousavi-jarrahi Y, Mousavi-jarrahi A. Cost of care for lung cancer in the first year after diagnosis in Iran. Asian Pac J Cancer Preven 2011; 12:1013-1015.
Nokiani FA, Akbari H, Rezaei M, Madami H, Agha MEA. Cost-effectiveness of pap smear in Kermanshah, Iran. Asian Pac J Cancer Preven 2008; 9:107-110.
Hatam N, Keshtkar V, Salehi A, Rafei H. The financial cost of preventive and curative programs for breast cancer: a case study of women in Shiraz-Iran. Int J Health Policy Manag 2014 May; 2:187-91.
Bahmei J, Rahimi H, Jafari AS, Habibyan M. Examination of medical and non-medical direct costs of outpatients and hospitalized cancer patients in Shiraz, Iran. Payesh 2015; 6: 629-637.
Ghaderi H, Vatankhah S, Khoshkam M, Rohani B. Estimation of Willingness to Pay for Mammographic Breast Cancer Screening Tests among Women in Tehran, Based On Contingent Valuation Method: 2010. Journal of Health Administration 2012; 15: 32-46.
Akbarzadehbaghban A, Esmaeili M, Kimiafar Kh. Medical Information Management and Assessment of Direct Costs of Treatment of Lung Cancer. Health Information Management 2008; 5:168.
Davari M, Moafi A, Yarmohammadian MH, Khayyam Haghighi E. The Direct Medical Costs of Acute Lymphocytic Leukemia (ALL) In Children in Isfahan Province. Health Inf Manage 2015;11: 1057.
Hayati H, Kebriaeezadeh A, Ehsani MA. Systematic Review of Treatment Costs for Pediatrics Acute Lymphoblastic Leukemia (Comparing Clinical Expenditures in Developed and Developing Countries). Int J Pediatr 2016; 4: 4033-4041
Nahvijou A, Sari AA, Zendehdel K, Marnani AB. Management of precancerous cervical lesions in Iran: a cost minimizing study. Asian Pac J Cancer Prev 2014; 15:8209-8213.
Ansaripour A, Uyl-de GC, Redekop WK. What is an efficient and affordable trastuzumab therapy in a middle-income country? Adjuvant therapy with trastuzumab in management of early HER2-positive breast cancer in Iran. Value Health 2016;19: A721.
Davari M, Ashrafi F, Maracy M, Aslani A, Tabatabaei M. Cost-effectiveness analysis of cetuximab in treatment of metastatic colorectal cancer in Iranian pharmaceutical market. Int J Prev Med 2015; 6: 63.
Barfar E, Rashidian A, Hosseini H, Nosratnejad S, Barooti E, Zendehdel K. Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women. Arch Iran Med 2014; 17:241-245.
Moridi M, Yusef N, Pasokhi M. Cost effectiveness of human papilloma-virus testing in cervical cancer diagnosis. Int J Fertil Steril 2013; 7:152-3.
Teimouri F, Nikfar S, Abdollahi M. Comparative efficacy and economic evaluation of dacarbazine and temozolomide in treatment of malignant melanoma in Iran. Value Health 2012;15: A656.
Allameh Z, Davari M, Emami MH. Cost-effectiveness analysis of colorectal cancer screening methods in Iran. Arch Iran Med 2011; 14:110-114.
Nassiripour L, Amirsadri M, Tabatabaeian M, Maracy MR. Cost-effectiveness of surgical excision versus Mohs micrographic surgery for nonmelanoma skin cancer: A retrospective cohort study. J Res Med Sci 2016; 21:91.
Hatam N, Ahmadloo N, Vazirzadeh M, Jafari A, Askarian M. Cost-Effectiveness of Intensive Vs. Standard Follow-Up Models for Patients with Breast Cancer in Shiraz, Iran. Asian Pac J Cancer Prev 2016; 17:5309-14.
Ehsani M, Kebriaeezadeh A, Nikfar S, Akbari SA, Shahgholi E, Yousefimanesh H. Cost-utility of protocols of ǣBFM ALLǥ and ǣUK ALLǥ for treatment of children with acute lymphoblastic leukemia in Iran. Pediatr Blood Cancer 2016;63: S105.
Nahvijou A, Daroudi R, Tahmasebi M, Amouzegar HF, Rezaei HM, Akbari SA. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: A middle-income country with a low incidence rate of cervical cancer. PLoS ONE 2016;11(6).
Haghighat S, Akbari ME, Yavari P, Javanbakht M, Ghaffari S. Cost-effectiveness of three rounds of mammography breast cancer screening in iranian women. Iran J Cancer Prev 2016; 9:1-8.
Zehtab N, Jafari M, Barooni M, Nakhaee N, Goudarzi R, Larry zadeh MH. Cost-Effectiveness Analysis of Breast Cancer Screening in Rural Iran. Asian Pac J Cancer Prev 2016; 17:609-614.
Hatam N, Dehghani M, Habibian M, Jafari A. Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory hodgkin and non-hodgkin lymphoma in Iran. Iran J Cancer Prev 2015;8(5).
Hatam N, Askarian M, Javan-noghabi J, Ahmadloo N, Mohammadianpanah M. Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran. Asian Pac J Cancer Prev 2015; 16:8265-8270.
Aboutorabi A, Hadian M, Ghaderi H, Salehi M, Ghiasipour M. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci 2015; 7:98-106.
Khatibi M, Rasekh HR, Shahverdi Z, Jamshidi HR. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Res 2014; 13:225-234.
Barouni M, Ghaderi H, Shahmoradi MK. The economic evaluation of screening for colorectal cancer: Case of Iran. Clin Lab 2013; 59:667-674.
Sari AA, Ravaghi H, Mobinizadeh M, Sarvari S. The cost-utility analysis of PET-scan in diagnosis and treatment of non-small cell lung carcinoma in Iran. Iran J Radiol 2013;10: 61-67.
Bastani P, Kiadaliri AA. Cost-utility analysis of adjuvant therapies for breast cancer in Iran. Int J Technol Assess Health Care 2012; 28:110-114.
Ahmad KA, Bastani P, Hatam N, Ahmadloo N. Cost-effectiveness analysis of cancer treatments in south of Iran. Value Health 2010;13(7): A267-A268.
Koopmans chap MA, Rutten FFH. The impact of indirect costs on outcomes of health care programs. Health Economics 1994; 3: 385-393.
Robinson R. Cost-utility analysis. BMJ1993; 307: 859 (doi:10.1136/bmj.307.6908.859)
Mcgregor M. Cost–utility analysis: Use QALYs only with great caution. CMAJ 2003, 168, 433-434.
Martins C, Godycki-cwirko M, Heleno B, Brodersen J. Quaternary prevention: reviewing the concept. European Journal of General Practice 2018, 24, 106-111.